Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402103 · ClinicalTrials.gov registry record · Phase 3
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 556
- Enrollment target
NCT00402103 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 556 participants.
The verdict
NCT00402103, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 556 participants
- Enrollment target
Study Summary
To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure \[msDBP\] ≥ 90 mmHg and \< 110 mmHg).
Interventions
- DRUG Amlodipine
- DRUG Aliskiren
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 556 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402103
The ClinicalTrials.gov registry entry for NCT00402103 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 556 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Amlodipine is the first listed.
NCT00402103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00402103 about?
NCT00402103 is a clinical study titled "An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure". To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure \[msDBP\] ≥ 90 mmHg and \< 110 mmHg).
What is the current status of trial NCT00402103?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 556 participants. The study started on 2006-11. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00402103?
The interventions under investigation include: Amlodipine (DRUG), Aliskiren (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00402103?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.